Splash celebration glitter
Pharma

$200M in 5 weeks: Behind RevMed's 'eye-popping' Rasonque debut

Generating $198 million in its first five weeks, Revolution Medicines’ RAS inhibitor daraxonrasib is living up to its much-hyped potential.
Fraiser Kansteiner Nov 5, 2026 11:11am
Resource Icon
The direct-to-patient DTP market is full of providers making bold claims But claims are not outcomes To unlock the true p

DTP – Delivering Proof Over Promise

Brought to you by Gifthealth
Driving Good Health car NASCAR

Boehringer drives liver health education at NASCAR races

Nov 5, 2026 10:54am
MA

AZ’s reported $10B offer for Rhythm fuels talks of a bidding war

Nov 5, 2026 9:36am
Job cuts employee layoffs firings or downsizing Scissors dividing individuals positioned on colorful blocks
Favicon Fierce Biotech

Agios shedding 100 R&D roles ahead of hoped-for SCD approval

Nov 5, 2026 8:40am
FDA

Vanda drives straight into FDA trouble with fast-paced Nereus ad

Nov 5, 2026 2:33am
More News

Merck eyes cancer-free finish line in new corporate campaign

Nov 4, 2026 3:43pm

Hundreds of Samsung Bio union members plan Nov. 6 strike

Nov 4, 2026 11:58am

Novo reports strong Q3 for Wegovy pill as potential launches loom

Nov 4, 2026 11:26am

Ex-Madrigal clinical head files Rezdiffra whistleblower suit

Nov 4, 2026 10:49am